WC
QNCX icon

Wexford Capital’s Quince Therapeutics QNCX Stock Holding History

Wexford Capital’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7
Closed -$40K – 313
2020
Q4 		$40K Buy
+7
New +$62K 0.01% 245

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wexford Capital's QNCX Position: Q1 2021 in Review

Wexford Capital sold out of Quince Therapeutics (QNCX) in Q1 2021, closing a stake of 7 shares — an estimated $40K sold.

Wexford Capital first reported a position in QNCX in Q4 2020 and held it in 1 quarter. The position peaked at $40K in Q4 2020. 86 funds tracked by Wall St. Rank hold QNCX as of Q1 2021.

  • Wexford Capital reported no remaining Quince Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Wexford Capital sold 7 Quince Therapeutics shares in Q1 2021, an estimated $40K.
  • Wexford Capital first reported a position in Quince Therapeutics in Q4 2020 and held it in 1 quarter.
  • Wexford Capital's Quince Therapeutics position peaked at $40K in Q4 2020.
  • 86 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2021.

Based on Wexford Capital's 13F filing for Q1 2021, filed 13 May 2021.